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Introduction
Gastroesophageal Cancer (GEc) is the eighth most 
common cancer in the world. The mortality rate of this 
cancer is estimated to exceed 407000 per year worldwide 
(Jemal et al., 2011). Despite outstanding advancements in 
managing this cancer, its 5- year survival is less than 20 
percent (Dikken et al., 2012). Treating locally advanced 
cancers remains challenging and unsatisfactory especially 
when the tumor attacks the adventitia layer or the adjacent 
structure (T3- T4) or in cases where the adjacent lymph 
nodes become involved (Ajani et al., 2005; Dikken et al., 
2012). A lot of effort is being made in increasing the survival 
of these patients. Preoperative chemotherapy (POC) based 
on cisplatin and fluorouracil drugs is often used before 
the surgery on patients suffering from gastroesophageal 
(GE) cancer. Although there is little evidence proving its 
effect on improving the prognosis, GE cancer still has a 
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poor prognosis (Sadighi et al., 2005; Dikken et al., 2012). 
Numerous clinical trial studies have been conducted with 
the aim to examine drug doses and drug schedules (phase 
1 researches), to evaluate the degree of responding to the 
drugs (phase 2 researches), and to evaluate the effect of 
a new medicine or a combination drug during a standard 
treating period on the overall survival in patients (phase 
3 researches) in order to make progress in managing the 
GE cancer (Ott et al., 2011; Lee et al., 2012). 
Pathologic Complete Response (PCR) is one of 
the initial indicators which indicates the success of 
preoperative chemoradiotherapy. PCR refers to the 
absence of live tumor cells in the microscope sample 
(histologic). A significant relationship has been also 
observed between PCR and an increase in patient survival 
in different meta- analyses and clinical trials (Ott et al., 
2011; Valenti et al., 2011; Pera et al., 2012). Although the 
definitive treatment for GE cancer (and in general, gastric 
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and esophageal cancer) is to surgically remove the entire 
tumor with clean microscopic margins, most patients still 
experience local and remote recurrence even after these 
types of surgeries (Sadighi et al., 2005; Jemal et al., 2011). 
All efforts are currently focused on systemic and local 
treatments before and after the surgery, surgery alone is 
not enough and the aim of prescribing the POC is to start 
the treatment at a time when the body tolerates the drug 
better and local and distant recurrences are prevented, so 
the disease stage decreases, the probability to increase the 
relapse- free survival and the total survival of the patient 
will therefore increase And eventually will increase the 
chances of successful operation (Ajani et al., 2005; Ott 
et al., 2011; Dikken et al., 2012; Lee et al., 2012). A 
number of preoperative and postoperative treatments have 
been examined in order to increase survival. Regarding 
advanced GE cancers, which include advanced local 
cases and metastatic diseases, the studies have revealed 
that palliative chemotherapy increases patient survival 
more than the best patient preservation treatments (Pera 
et al., 2012). 
Many treatment protocols have been suggested 
in this filed which include chemotherapy protocols 
based on cisplatin, docetaxel, oxaliplatin, and edible 
fluoropyrimidines (Archie et al., 2006; Shigeoka et al., 
2010; Pera et al., 2012). There is no specific treatment 
regimen as the gold standard and the proper regimens 
are the ones which are based on a combination of one 
of the platinum substances (cisplatin or oxaliplatin) and 
a fluoropyrimidine (such as FU- 5 or capecitabine). An 
additional selection is based on adding epirubicin or 
docetaxel to the above- mentioned substances (Sadighi 
et al., 2005; Valenti et al., 2011; Pera et al., 2012). With 
regard to the fact that limited number of researches have 
been conducted in Iran on preoperative chemotherapy, 
we have carried out the present research with the aim 
to evaluate the tumor resectability after preoperative 
chemotherapy, pathological response and postoperative 




This research conducted as a  retrospective cross- sectional 
and study on 156 patients between 18 to 80 years old 
suffering from gastroesophageal cancer (GEc) between 
2013 and 2015 at Shariati Hospital of Tehran. The patients 
were enrolled in the research after obtaining informed 
consent. We designed this comparative study based on two 
groups, the first group of patients had previously received 
preoperative chemotherapy and the second group had 
only undergone surgery (SA). All patients were followed 
for at least one year after the operation in terms of tumor 
recurrence, relapse free survival and one- year survival. 
The two groups were eventually examined and compared 
with each other regarding tumor resection, pathological 
response, postoperative complications, recurrence rate and 
survival. The data were collected through patient records, 
examinations and following up the participants. 
The inclusion criteria for participating in the study 
were as follows: the participants had to fill out the 
informed consent form, 18 to 80 years old, lose less 
than 5% weight within 3 months before participating 
in the study, the patients must not have experienced 
undergoing chemotherapy and radiation to the abdomen, 
presence of initial malignancies or other main associate 
diseases. Absence of distant metastasis including the 
lungs, bone, brain, and liver and ascites. The exclusion 
criteria were included following items : metastasis, 
history of sensitivity to chemotherapy drugs, infection and 
fever, pregnancy and breastfeeding, other malignancies 
within the past 5 years, not undergoing surgery after 4 
weeks from the first chemotherapy, irreversible effects 
of preoperation chemotherapy and The patient’s 
unwillingness to participate in the study.
All patients of the first group were received the 
following drug regimen: 100 mg epirubicin (IV) and 200 
mg of oxaliplatin 100 (IV) in the first day and 24- hour 
infusion of 400 milligrams of 5- fluoropyrimidine in 
days 1 through 21. The above- mentioned regimen was 
repeated for all the patients in 3, 21- day periods and in 
case of the occurrence of drug- dependent toxicity such 
as neutropenia, anemia, nausea and vomiting, diarrhoea, 
neuropathy, and etc., the drugs doses were adjusted or 
discontinued. Total gastrectomy surgery or esophagectomy 
surgery (reconstructive) was carried out along with 
lymphadenectomy four weeks after the last dose of 
preoperative chemotherapy and the resectability rate 
was assessed during the surgery. All the surgeries were 
performed simultaneously by two sufficiently- experienced 
surgeons in the field of gastroesophageal malignancy 
operations and postoperative complications such 
as anastomotic leaks, pneumonia, respiratory failure, 
surgical infection, ileus, and etc. were noted down. 
Checklist, examinations, pathology and radiology reports, 
surgeon’s observations, and the information in the files 
of the patients were used to collect the data required 
by this research. After collecting the essential data, the 
data were analyzed with version 22 of SPSS software. 
The continuous variables are reported as means±SD, 
and categorical variables are reported by number and 
percentage. Normality for continuous variables was 
determined by the Kolmogorov-Smirnov test, which 
revealed that the continuous variables showed normal 
distributions (P>0.05). The unpaired t test was used for 
comparison of variables between groups. For statistical 
evaluation of categorical variables, we used the chi-square 
test and Fisher exact test as appropriate. P values of <0.05 
were considered as significant.
 
Results
A total of 156 patients were examined in the present 
research. They were placed into two groups the first group 
included the patients who had received POC (100 mg 
epirubicin, 200 mg of oxaliplatin, and 400 mg of 5- FU) 
before the surgery and the second group included the 
patients who only underwent the operation. The findings 
demonstrated that the mean and SD of the age is 66.5± 
7.3 years. The age range of the under- study individuals 
was 25 to 80 years and they were classified in six groups. 
Most of the patients were 60- 70 years old and the minority 
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were 30 to 40 years old. Also 123 under- study individuals 
were male (78.2 %) and 33 of them were female (21.2 
%) (Table 1). 
Based on the findings of the present research, a 
significant relationship was seen between receiving POC 
and tumor resection in such a manner that almost 74% 
of the patients of the first group had a resectable tumor 
while only 63% of the patients of the second group had 
resectable tumors that was statistically significant (P < 
0.005). Of 78 patients who had received Neoadjuvant, 
36 (46.2%) individuals had a pathologic relative response 
(G1), 32.1 % had a pathologic incomplete response (G2), 
and only 21.8 % of the patients had a pathologic complete 
response (G3) (Table 2). postoperative complications 
have a different distribution in the two groups in such 
a manner that ileus, anastomotic leaks, pneumonia, and 
peritonitis (infection) and bleeding were not significantly 
different in the two groups (P> 0.05) the two groups 
were however significantly different regarding wound 
dehiscence (P< 0.08 in first group vs. P< 0.02 in second 
group), also seroma formation was not reported in any of 
the groups. Comparing the tumor- staging findings before 
Neoadjuvant therapy and after the surgery indicates that 
preoperative chemotherapy has a significant impact on 
reducing the tumor stage (P< 0.01). Based on the opinion 
of the surgeon the tumor recurrence was approximately 
31.1 % in the group which had received Neoadjuvant. 
Tumor recurrence was however almost 57.8 % in patients 
who had only undergone the surgery which is statistically 
significant (P< 0.05). Also a significant difference was 
seen between the two groups regarding the time without 
disease and the one- year survival values (P< 0.01 and 





P- valueChemotherapy and Surgery 
(n = 78)
Surgery Alone (n = 78)
No. % No. % %
Age (y) Mean (SD) 62.8 (6.33) 60.3 (8.1) 61.56 (7.33) P>0.05
sex male 58.0 74.4 65.0 83.3 78.8 0.17
female 20.0 25.6 13.0 16.7 21.2
WHO performance 
status
1.0 16.0 52.6 5.0 6.4 13.5 0.03
2.0 41.0 20.5 47.0 60.3 56.4
>2.0 21.0 26.9 26.0 33.3 30.1
Histologic subtype Intestinal 19.0 24.4 18.0 23.1 23.7 0.14
Nonintestinal 40.0 51.2 48.0 61.5 56.4
(diffuse)
Scc 12.0 24.4 12.0 15.4 19.9
Differentiation of tumor Poor 25.0 32.1 30.0 38.5 35.3 0.70
Moderate 42.0 53.8 38.0 48.7 51.3
Well 11.0 14.1 10.0 12.8 13.5
T category across 
different staging 
methods
T2 3.0 3.8 2.0 2.6 3.2 0.63
T3 62.0 79.5 58.0 74.4 76.9
T4 13.0 16.7 18.0 23.1 19.9
N category across 
different staging 
methods
N0 7.0 9.0 22.0 28.2 18.6 <0.01
N1 35.0 44.9 19.0 24.4 34.6
N2 33.0 42.3 37.0 47.4 44.9
N3 3.0 3.8 0.0 0.0 1.9
M category 
across different staging 
methods
M0 53.0 67.9 60.0 76.9 72.4 0.01
M1 17.0 21.8 18.0 23.1 22.4
Missing 8.0 10.3 0.0 0.0 5.1
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P< 0.03, respectively) based on the findings of our study 
(Table 3).
Discussion
Although the definitive treatment for GE cancer (and 
in general, gastric and esophageal cancer) is to surgically 
remove the entire tumor with clean microscopic margins, 
most patients still experience local and distant recurrence 
even after operation. Today, Different researches have 
clearly demonstrated that surgery alone is not enough 
and all efforts are currently focused on systemic and 
local treatments before and after the surgery, the aim 
of prescribing POC is to start the treatment at a time 
when the body tolerates the drug better and local and 
distant recurrences are prevented and the possibility 
that the surgery will succeed increases. Different 
researches with numerous treatment regimens have been 
conducted on the effect of POC on tumor resectability, 
pathological response, postoperative complications, 
tumor recurrence, and patient survival which have 
resulted more or less similar outcomes. In contrast, there 
are researches which have not obtained good results 
regarding using POC (Flamant Y, 1999; Cunningham et 
al., 2006). It was seen based on our findings that there 
is a significant relationship between receiving POC and 
tumor resectability. 73 individuals (93.5%) of the total 
78 people who had received POC were resectable while 
Table 2. Other Characteristics of Patients According to Treatment Assignment
Clinical findings Levels
Treatment Total
P- valueChemotherapy and Surgery (n = 72) Surgery Alone (n = 72)
No. % No. % %
Resection R0 5.0 6.4 17.0 21.8 14.1 <0.01
R1 73.0 93.6 61.0 78.2 85.9
Pathological response to 
neoadjuant
G0 * 17.0 21.8 - - 21.8 -
G1 36.0 46.2 - - 46.2
G2 25.0 32.1 - - 32.1
Recurrence Yes 24.0 31.1 44.0 57.8 44.4 0.05
No 53.0 68.9 32.0 42.2 55.6
Time without disease Mean (± sd) 17.5(0.6) 13.9 (0.6) < 0.01
month
Operating time Mean (± sd) 3.8 (0.6) 3.8 (0.5) 0.89
hour
The one-year survival Live 62.0 79.5 52.0 66.7 73.1 0.03
Died 16.0 20.5 26.0 33.3 26.9








Surgery Alone (n = 78)
No. % No. % No. %
Tumor location Cardia 39.0 50.0 43.0 55.1 82.0 52.6
Distal of esophagus 15.0 19.2 10.0 12.8 25.0 16.0
GEj 24.0 30.8 25.0 32.1 49.0 31.4
degree ll 11.0 14.1 26.0 33.3 37.0 23.7
lll 65.0 83.3 49.0 62.8 114.0 73.1
missing 2.0 2.6 3.0 3.8 5.0 3.2
Resectin margin R0 66.0 84.6 57.0 73.1 123.0 78.8
R1 12.0 15.4 21.0 26.9 33.0 21.2
Lymphnode 
ivvolved
N+ 30.0 38.5 60.0 76.9 90.0 57.7
N- 48.0 61.5 18.0 23.1 66.0 42.3
Table 3. Summary of Pathological Findings
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groups indicates that no tumor cells were seen in the 
margin of the removed tissue (R0) in almost 85% of the 
patients in the POC group while this was true for almost 
73% of the patients who underwent surgery alone (P< 
0.058). In a retrospective clinical trial study, no tumor 
cells were seen in the margin of the removed tissues 
in 94 percent (R0) of the patients who had received 
Cisplatin which was better than our study. It is also worth 
mentioning that based on the findings of this study and 
comparing them with the findings of tumor staging before 
POC and after surgery, chemotherapy has had a significant 
impact in reducing the tumor stage (P< 0.01) (Ando et al., 
2003; Allum et al., 2009).
Based on the opinion of the surgeon, tumor recurrence 
was seen in almost 31.1% of the POC group but it was 
57.8% in the second group (P<0.05). Tumor recurrence was 
different in studies conducted in different countries and 
it seems like due to the different in the target population 
and the cells involved, the pathological response to 
Neoadjuvant depends on the expertise of the surgeon 
and etc. most of the researches which have been 
conducted in this field approve that using a standard 
treatment regimen significantly increases the possibility 
of tumor recurrence. For example a clinical trial research 
reported the tumor recurrence in the POC group and the 
surgery alone group 29 and 50%, respectively (P<0.01) . 
Some other studies however claimed that although using 
POC decreases tumor recurrence in short- term, it does 
not have a noticeable and significant effect of distant 
recurrence of the tumor (Flamant Y, 1999; Urba et al., 2001; 
Weber et al., 2001). It has also been reported in different 
studies that in addition to decreasing the possibility of 
tumor recurrence in comparison with surgery alone group, 
the use of POC significantly increases the disease- free 
time or the time period between the surgery and tumor 
recurrence. This was also obtained in our study in such a 
manner that the mean disease- free time was 17.45 months 
in the POC group and 13.92 months in the surgery alone 
group which was statistically significant (P< 0.01). It must 
also be noted that based on our study, the patients who 
had been treated with POC needed lesser postoperative 
chemotherapy (P< 0.04).
Based on the findings of this research the one- year 
survival of the patients in the first group was greater than 
that of the second group. The one- year survival of the 
patients of the first group was 79.5% and 66.5% in the 
second group (P< 0.03). On the basis of the researches 
conducted in this field, including an RCT study which 
demonstrated that the five- year survival of the patients 
in the POC group was 36% versus 23% (P< 0.01) (Law 
et al., 1997; Weber et al., 2001), the results of John 
Urschel’s meta- analysis (Urschel and Vasan, 2003) 
(consisting of 9 randomized clinical trials: 116 patients) 
indicates that the one- year, two- year, and three- year 
survival of the preoperative chemotherapy group was 79, 
77, and 66 percent, respectively, which was similar with 
our study. Moreover, based on the results obtained from 
this study the survival of the patients in the groups which 
had used a combination of POC and chemoradiotherapy 
was estimated to be greater than the group which had 
only 60 (76%) individuals in the second group (P< 0.01) 
were resectable. The results of a clinical trial study with 
(paclitaxel/ 5w) treatment regimen indicated that the tumor 
had completely resected in 92 percent of the patients of 
POC group which was significantly different from the 69% 
in the surgery alone group (P< 0.01). In contrast to this 
study, another RCT study in America showed that the two 
groups are almost similar in terms of tumor resection. But 
the tumor was however significantly smaller in the group 
that had received POC and fewer cases of advancement 
were seen in them (Urba et al., 2001; Ando et al., 2003).
Postoperative complication distribution was different 
in the patients. The complications were generally 
less frequent in the POC group in comparison to the surgery 
alone group (14 cases vs 19 cases). Ileus, anastomotic leaks, 
pneumonia, and peritonitis (infection) and bleeding were 
not significantly different in the two groups (P> 0.05). 
There was however a significant statistical difference 
regarding wound dehiscence (P< 0.03). The most frequent 
reported complications was anastomotic leak with 10 
cases which included 30 percent of all the complications 
it is also worth mentioning that seroma was not formed 
in any of the patients. In a retrospective trial study with 
a combination treatment regimen of cisplatin and FU-5, 
comparing the results of complications occurring during 
the operation and postoperative complications indicated 
that only bleeding during the surgery and anastomotic 
leaks were significantly different in the two groups (P< 
0.05) all the other matters were not significantly different. 
Based on the findings of this study, the surgery duration 
(P= 0.983), blood loss during the operation (P= 0.84), 
and tumor differentiation from the neighbouring tissues 
were not significantly different which is similar to the 
results of the studies which were conducted in this field 
(Cunningham et al., 2006; Shigeoka et al., 2010; Ychou 
et al., 2011).
36 (46.2%) individuals from amongst the total of 
78 patients in our study who had received POC had a 
relative pathological response, 32.1 % had an incomplete 
pathological response, and 21.8 % of the patients had a 
pathologic complete response (PCR). PCR is considered 
the absence of the remains of the tumor in surgical samples 
which is one of the factors indicating the success of the 
surgery. The researches of other researchers resulted in 
similar findings which were consistent with our study. 
One of these researches was a second- phase trial study 
which used (oxaliplatin, cisplatin, and 5-FU) treatment 
regimen for 6 to 8 weeks. The result indicated that PCR 
was seen in 25 percent of the gastroesophageal junction 
cancer cases (Cunningham et al., 2006). Another research 
demonstrated that PCR was seen in 33% of the patients 
who were being treated with POC which was similar to 
the results obtained from Khaldoun Almhanna et al.’s 
research in Florida (25%). In Simon’s study however, the 
PCR to chemotherapy was 58% while only 6.7% of the 
patients were affected by PCR (Kelsen et al., 1998; Urba 
et al., 2001; Ychou et al., 2011).
Also comparing the surgery margin pathology (SMP) 
frequency distribution (the presence of tumor cells in the 
margin of the removed tissue) in the two under- study 
Aref Kashefi Marandi et al
Asian Pacific Journal of Cancer Prevention, Vol 17, Cancer Control in Western Asia Special Issue, 2016236
to neoadjuvant chemoradiotherapy in esophageal carcinoma 
is associated with significantly improved survival. J Clin 
Oncol, 23, 4330-37.
Cunningham D, Allum WH, Stenning SP, et al (2006). 
Perioperative chemotherapy versus surgery alone for 
resectable gastroesophageal cancer. N Engl J Med, 355, 
11-20.
Dikken JL, van de Velde CJ, Coit DG, et al (2012). Treatment 
of resectable gastric cancer. Therap Adv Gastroenterol, 5, 
49-69.
Flamant Y CJ, Huguier M, Quandalle P, et al  (1999). 
Chimiothérapie  adjuvante  après  résect ion des 
adénocarcinomes gastriques: étude prospective contrôlée 
de l’effet de l’association 5FU, acide folinique et cisplatine. 
Gastroenterol Clin Biol, 21, 16.
Gebski V, Burmeister B, Smithers BM, et al (2007). Survival 
benefits from neoadjuvant chemoradiotherapy or 
chemotherapy in oesophageal carcinoma: a meta-analysis. 
Lancet Oncol, 8, 226-34.
Information on the Dutch CRITICS trial [Online]. Available: 
http://clinicaltrials.gov/ct2/show/NCT00407186 [Accessed 
14 December 2010].
Jemal A, Bray F, Center MM, et al (2011). Global cancer 
statistics. CA Cancer J Clin, 61, 69-90.
Kelsen DP, Ginsberg R, Pajak TF, et al (1998). Chemotherapy 
followed by surgery compared with surgery alone for 
localized esophageal cancer. N Engl J Med, 339, 1979-84.
Law S, Fok M, Chow S, et al (1997). Preoperative 
chemotherapy versus surgical therapy alone for squamous 
cell carcinoma of the esophagus: a prospective randomized 
trial. J Thorac Cardiovasc Surg, 114, 210-7.
Lee DJ, Sohn TS, Lim DH, et al (2012). Phase I study of 
neoadjuvant chemoradiotherapy with S-1 and oxaliplatin 
in patients with locally advanced gastric cancer. Cancer 
Chemother Pharmacol, 69, 1333-38.
Ott K, Lordick F, Blank S, et al (2011). Gastric cancer: surgery 
in 2011.  Langenbecks Arch Surg, 396, 743-58.
Pera M, Gallego R, Montagut C, et al (2012). Phase II trial of 
preoperative chemoradiotherapy with oxaliplatin, cisplatin, 
and 5-FU in locally advanced esophageal and gastric cancer. 
Ann Oncol, 23, 664-70.
Sadighi S, Raafat J, Mohagheghi M, et al (2005). Gastric 
carcinoma: 5 year experience of a single institute. Asian 
Pac J Cancer Prev, 6, 195-6.
Shigeoka H, Imamoto H, Nishimura Y, et al (2010). Complete 
response to preoperative chemoradiotherapy in highly 
advanced gastric adenocarcinoma. World J Gastrointest 
Oncol, 2, 282-6.
Urba SG, Orringer MB, Turrisi A, et al (2001). Randomized 
trial of preoperative chemoradiation versus surgery alone 
in patients with locoregional esophageal carcinoma. J Clin 
Oncol, 19, 305-13.
Urschel JD, Vasan H (2003). A meta-analysis of randomized 
controlled trials that compared neoadjuvant chemoradiation 
and surgery to surgery alone for resectable esophageal 
cancer.  Am J Surg, 185, 538-43.
Valenti V, Hernandez-Lizoain JL, Beorlegui MC, et al (2011). 
Morbidity, mortality, and pathological response in patients 
with gastric cancer preoperatively treated with chemotherapy 
or chemoradiotherapy. J Surg Oncol, 104, 124-9.
Weber WA, Ott K, Becker K, et al (2001). Prediction of response 
to preoperative chemotherapy in adenocarcinomas of the 
esophagogastric junction by metabolic imaging. J Clin 
Oncol, 19, 3058-65.
Working MRCOC (2002). Surgical resection with or without 
preoperative chemotherapy in oesophageal cancer: a 
randomised controlled trial. Lancet, 359, 1727-33.
been treated with chemotherapy or radiotherapy alone. 
However, despite all the numerous studies which have 
been carried out about the outstanding effect of using 
POC to increase the patient survival chances, there 
are a few studies which state that chemotherapy and 
chemoradiotherapy do not affect the total survival rate 
of the patients and they only prolong the postoperative 
disease- free time and decrease the mortality rates caused 
by cancer (Working, 2002; Berger et al., 2005; Gebski et 
al., 2007).
The performance status of the patients was evaluated in 
both groups in this study based on WHO performance scale 
(0-5). The performance status of the patients was better in 
the first group after the surgery in comparison with the 
second group (P< 0.04). This variable is of importance 
since approximately half of the patients suffering 
from GE cancer do not have the physical conditions to 
undergo the surgical procedure. In other words, they are 
unable to tolerate the surgery and 20- 30 percent of the 
patients who are in better conditions will be affected by 
respiratory problems and 10- 15 percent will have major 
heart problems which eventually leads to losing the 
patient. Therefore adopting proper protocols for using 
Neoadjuvant before the surgery could improve the general 
status of the patient, decrease the disease’s recurrence 
changes or delay it, decrease mortality and increase patient 
survival rate. 
Based on the findings of the present research and the 
other researchers conducted in this field, using standard 
regimens of Neoadjuvant (preoperative chemotherapy/ 
chemoradiotherapy) before the operation could increase 
tumor resectability, increase the pathological response, 
and improve the general status of the patients, therefore 
using POC is preferred to surgery alone.
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